Discontinuing directly acting antivirals during hepatitis C treatment: highlighting an infrequent but hostile event
- 22 October 2022
- journal article
- letter
- Published by Elsevier in Clinics and Research in Hepatology and Gastroenterology
- Vol. 46 (10) , 102042
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Uncertainty and Cures: Discontinuation, Irreversibility, and Outcomes-Based Payments: What Is Different About a One-Off Treatment?Value in Health, 2019
- Towards hepatitis C virus elimination: Egyptian experience, achievements and limitationsWorld Journal of Gastroenterology, 2018
- An account of the real-life hepatitis C management in a single specialized viral hepatitis treatment centre in Egypt: results of treating 7042 patients with 7 different direct acting antiviral regimensExpert Review of Gastroenterology & Hepatology, 2018
- Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohortJournal of Hepatology, 2017
- Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patientsLiver International, 2016
- Safety of direct antiviral agents in the management of hepatitis CExpert Opinion on Drug Safety, 2016
- New era for management of chronic hepatitis C virus using direct antiviral agents: A reviewJournal of Advanced Research, 2015
- Sofosbuvir for Previously Untreated Chronic Hepatitis C InfectionNew England Journal of Medicine, 2013